semaglutide and cardiovascular outcomes in obesity without diabetes journal club Long-term weight loss effects of in the SELECT trial Cardiovascular Outcomes, Safety, and Tolerability

Unlike appetite suppressants, GLP-1 receptor agonists offer a dual benefit: improved glycemic control for individuals with type 2 diabetes and support for weight reduction

What's New: TRIUMPH-1 Announced (May 21, 2026) Results announced: May 21, 2026 Eli Lilly press release Trial status: Complete all primary and key secondary endpoints met Key result: 28.3% average weight loss at 80 weeks (12mg dose, N=2,339) NDA impact: Eli Lilly now has the primary efficacy dataset required for Q4 2026 NDA filing Next trial to watch: TRIUMPH-2 (diabetes) expected Q3Q4 2026 Introduction On May 21, 2026, Eli Lilly announced the topline results of TRIUMPH-1 the pivotal Phase 3 trial that determines whether retatrutide will receive FDA approval for obesity treatment

And there, there, as you know, there are reasons to do both

If your fatigue doesnt improve with lifestyle adjustments to your sleep, nutrition, and hydrationespecially if youre past 4 weeks of taking the medicationthen talk with a healthcare professional, like a Midi clinician